Loading
Adding drugs to the catheter procedure keeps intermediate-stage liver cancer under control for longer, though a survival gain is still unproven.
This combination adds immune checkpoint inhibitors, with or without anti-VEGF therapy, to transarterial chemoembolisation for intermediate-stage hepatocellular carcinoma. TACE releases tumour antigen and induces hypoxia-driven VEGF; PD-1 or PD-L1 blockade exploits the former and anti-angiogenic therapy counters the latter. Three phase 3 trials, EMERALD-1, LEAP-012 and EMERALD-3, all improved progression-free survival, but LEAP-012's final overall survival analysis and EMERALD-1's non-significant trend leave the survival question open. Toxicity roughly doubles with the added drugs, so the trade-off is longer disease control against more side effects without a proven gain in survival.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Shares EMERALD-1, Transarterial chemoembolisation (TACE), Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Shares LEAP-012, Intermediate hepatocellular carcinoma (BCLC B).
Shares EMERALD-1, Intermediate hepatocellular carcinoma (BCLC B).
Shares Intermediate hepatocellular carcinoma (BCLC B), Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Intermediate hepatocellular carcinoma (BCLC B), Anti-angiogenic therapy, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Intermediate hepatocellular carcinoma (BCLC B), Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/